keyword
MENU ▼
Read by QxMD icon Read
search

Secukinumab

keyword
https://www.readbyqxmd.com/read/27862942/a-novel-xenogeneic-graft-versus-host-disease-model-for-investigating-the-pathological-role-of-human-cd4-or-cd8-t-cells-using-immunodeficient-nog-mice
#1
Ryoji Ito, Ikumi Katano, Kenji Kawai, Mika Yagoto, Takeshi Takahashi, Yuyo Ka, Tomoyuki Ogura, Riichi Takahashi, Mamoru Ito
Graft-versus-host disease (GVHD) is a major complication of allogenic bone marrow transplantation and involves the infiltration of donor CD4+ and/or CD8+ T cells into various organs of the recipient. The pathological role of human CD4+ and CD8+ T cells in GVHD remains controversial. In this study, we established two novel xenogeneic (xeno)-GVHD models. Human CD4+ or CD8+ T cells were purified from peripheral blood and were transplanted into immunodeficient NOD/Shi-scid IL2rg(null) (NOG) mice. Human CD8+ T cells did not induce major GVHD symptoms in conventional NOG mice...
November 15, 2016: American Journal of Transplantation
https://www.readbyqxmd.com/read/27856660/effect-of-il-17-receptor-a-blockade-with-brodalumab-in-inflammatory-diseases
#2
REVIEW
Ajay Nirula, Jon Nilsen, Paul Klekotka, Greg Kricorian, Ngozi Erondu, Jennifer E Towne, Chris B Russell, David A Martin, Alison L Budelsky
IL-17 cytokines are expressed by a variety of cells and mediate host defence against extracellular pathogens. IL-17 is upregulated at sites of inflammation and can synergize with other cytokines, such as TNF-α, to amplify the inflammatory response. Activation of these signalling pathways has been hypothesized to contribute to the underlying pathogenesis of several inflammatory diseases, including psoriasis, RA, PsA and asthma. Thus the IL-17 signalling pathway is an attractive target for the development of therapeutic agents to modulate aberrant inflammatory responses...
December 2016: Rheumatology
https://www.readbyqxmd.com/read/27856659/new-treatment-targets-for-axial-spondyloarthritis
#3
REVIEW
Joachim Sieper
Axial spondyloarthritis (axSpA) patients can be divided into those with structural damage in the SI joint visible on X-rays, termed radiographic axSpA or AS, and those in an earlier phase of the disease, without structural damage in the SI joint, termed non-radiographic axSpA. TNF-blockers have been shown to be highly effective in the treatment of active axSpA. Interestingly, conventional DMARDs and also non-TNF-blocker biologics targeting IL-1, IL-6 and T cells (abatacept) are not effective. Recent interest has focused on the cytokines IL-23 and IL-17 as potential treatment targets in axSpA...
December 2016: Rheumatology
https://www.readbyqxmd.com/read/27856658/new-targets-in-psoriatic-arthritis
#4
REVIEW
Juergen Braun
PsA is an immune-mediated chronic inflammatory disease that affects both skin and joints; it is a heterogeneous disease characterized by synovitis, enthesitis, dactylitis and spondylitis. The impact on patients and the burden of disease are substantial. For assessment of the disease, patient-reported outcomes are increasingly important. Conventional therapy consists of NSAIDs, local and systemic CSs, and synthetic and biological DMARDs. While MTX, LEF, SSZ and CYC are the synthetic drugs mainly used, TNF-α blocking agents have represented the majority of biologics used in the last decade (infliximab, etanercept, adalimumab, certolizumab and golimumab)...
December 2016: Rheumatology
https://www.readbyqxmd.com/read/27836567/management-of-psoriatic-arthritis-early-diagnosis-monitoring-of-disease-severity-and-cutting-edge-therapies
#5
REVIEW
Siba P Raychaudhuri, Reason Wilken, Andrea C Sukhov, Smriti K Raychaudhuri, Emanual Maverakis
Psoriatic arthritis (PsA) is a heterogeneous disease that can involve a variety of distinct anatomical sites including a patient's peripheral and axial joints, entheses, skin and nails. Appropriate management of PsA requires early diagnosis, monitoring of disease activity, and utilization of cutting edge therapies. To accomplish the former there are a variety of PsA-specific tools available to screen, diagnose, and assess patients. This review will outline the recently developed PsA screening tools, including the Toronto Psoriatic Arthritis Screening Questionnaire (TOPAS), the Psoriasis Epidemiology Screening Tool (PEST), the Psoriatic Arthritis Screening and Evaluation (PASE), and the Psoriasis and Arthritis Screening Questionnaire (PASQ)...
November 8, 2016: Journal of Autoimmunity
https://www.readbyqxmd.com/read/27832717/secukinumab-provides-better-relief-from-the-impact-of-psoriasis-on-daily-activities-and-personal-relationships-than-etanercept-results-of-two-phase-3-placebo-controlled-randomized-clinical-trials-in-moderate-to-severe-psoriasis
#6
Neil J Korman, Howard Sofen, Scott Fretzin, Phoebe Rich, Yang Zhao, Vivian Herrera, Judit Nyirady, Nicole Williams, Margaret Mordin, Stephen Tyring
BACKGROUND: Psoriasis can greatly impact patients' lives, influencing what clothing they wear and impairing their sexual functioning. OBJECTIVE: To provide a detailed comparison of the impact of secukinumab versus etanercept on enabling patients with psoriasis to have more normal lives with respect to daily activities (e.g., choosing clothing) and personal relationships (e.g., sexual functioning). METHODS: Baseline to Week 52 ERASURE and FIXTURE data for secukinumab 300 mg and etanercept were analyzed...
November 11, 2016: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/27829672/management-of-psoriatic-arthritis-in-2016-a-comparison-of-eular-and-grappa-recommendations
#7
REVIEW
Laure Gossec, Laura C Coates, Maarten de Wit, Arthur Kavanaugh, Sofia Ramiro, Philip J Mease, Christopher T Ritchlin, Désirée van der Heijde, Josef S Smolen
Psoriatic arthritis (PsA) is a heterogeneous, potentially severe disease. Many therapeutic agents are now available for PsA, but treatment decisions are not always straightforward. To assist in this decision making, two sets of recommendations for the management of PsA were published in 2016 by international organizations - the European League Against Rheumatism (EULAR) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). In both sets of recommendations, the heterogeneity of PsA is recognized and the place of various drugs in the therapeutic armamentarium is discussed...
November 10, 2016: Nature Reviews. Rheumatology
https://www.readbyqxmd.com/read/27826996/treatment-of-psoriatic-arthritis-with-traditional-dmard-s-and-novel-therapies-approaches-and-recommendations
#8
Ajesh B Maharaj, Vinod Chandran
Recent advances in the therapeutics of psoriatic arthritis (PsA) have provided more options to clinicians managing PsA. The purpose of this review is to update the reader on treatment options for PsA using conventional synthetic disease modifying agents (csDMARDs) and novel therapies including tumour necrosis factor alpha inhibitors, interleukin 12/23 inhibitor (ustekinumab), the interleukin 17 antagonists including secukinumab, brodalumab, ixekizumab, and the phosphodiesterase-4 inhibitor, apremilast. Areas covered: We reviewed published articles on the treatment of PsA...
November 18, 2016: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/27799780/secukinumab-for-ankylosing-spondylitis-and-psoriatic-arthritis
#9
REVIEW
Ennio Lubrano, Fabio Massimo Perrotta
The treatment of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) positively changed since the introduction of anti-TNFα drugs. These treatments were shown to reduce the symptoms and signs of the diseases and improve the quality of life. However, a variable percentage of patients do not respond to anti-TNFα or can exhibit a loss of response and, furthermore, despite anti-TNFα drugs' proven efficacy in reducing peripheral radiographic progression in PsA, the impact in reducing radiographic damage in AS is still debated...
2016: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/27789419/exacerbation-of-depression-in-a-psoriatic-arthritis-patient-possibly-induced-by-secukinumab
#10
Takaya Komori, Atsushi Otsuka, Yuki Honda, Shuto Kanameishi, Tetsuya Honda, Kenji Kabashima
No abstract text is available yet for this article.
October 1, 2016: European Journal of Dermatology: EJD
https://www.readbyqxmd.com/read/27785085/treatment-challenges-in-the-management-of-moderate-to-severe-plaque-psoriasis-role-of-secukinumab
#11
REVIEW
Mona Malakouti, Sharon E Jacob, Nancy J Anderson
Psoriasis is a chronic inflammatory skin disease that has a negative impact on psychosocial well-being and cardiometabolic health. Treatment options for moderate-to-severe psoriasis have expanded with the development of interleukin-17 (IL-17) inhibitors, the first of which is now available - secukinumab. Secukinumab is a fully human monoclonal immunoglobulin G1 κ antibody that selectively inhibits the ligand IL-17A. In head-to-head studies, it is more effective than etanercept and ustekinumab, particularly in achieving Psoriasis Area and Severity Index (PASI) 90/100 and achieving PASI 50/75 as early as week 4...
2016: Clinical, Cosmetic and Investigational Dermatology
https://www.readbyqxmd.com/read/27752531/severe-ulcerative-lichenoid-mucositis-associated-with-secukinumab
#12
Jordan M Thompson, Lisa M Cohen, Catherine S Yang, George Kroumpouzos
No abstract text is available yet for this article.
September 2016: JAAD Case Reports
https://www.readbyqxmd.com/read/27748259/drug-eruption-caused-by-secukinumab
#13
Mayu Shibata, Yu Sawada, Takashi Yamaguchi, Shun Ohmori, Daisuke Omoto, Sanehito Haruyama, Manabu Yoshioka, Etsuko Okada, Motonobu Nakamura
No abstract text is available yet for this article.
October 17, 2016: European Journal of Dermatology: EJD
https://www.readbyqxmd.com/read/27747581/network-meta-analysis-and-cost-per-responder-of-tumor-necrosis-factor-%C3%AE-and-interleukin-inhibitors-in-the-treatment-of-active-ankylosing-spondylitis
#14
Keith A Betts, Jenny Griffith, Yan Song, Manish Mittal, Avani Joshi, Eric Q Wu, Arijit Ganguli
INTRODUCTION: Biologic therapies have improved the clinical management of ankylosing spondylitis (AS). Few head-to-head studies have directly compared the efficacy of these agents. This study was conducted to indirectly compare the efficacy of biologic agents for treatment of active AS. METHODS: A targeted literature review was conducted to identify randomized clinical trials for adalimumab, infliximab, golimumab, certolizumab pegol, etanercept, and secukinumab for the treatment of active AS...
December 2016: Rheumatology and Therapy
https://www.readbyqxmd.com/read/27747580/erratum-to-secukinumab-a-new-treatment-option-for-psoriatic-arthritis
#15
Philip Mease, Iain B McInnes
No abstract text is available yet for this article.
December 2016: Rheumatology and Therapy
https://www.readbyqxmd.com/read/27747518/secukinumab-a-new-treatment-option-for-psoriatic-arthritis
#16
Philip Mease, Iain B McInnes
INTRODUCTION: Psoriatic arthritis (PsA) is an immune-mediated chronic inflammatory arthropathy associated with impaired physical function and reduced quality of life. Biologic therapies that target tumor necrosis factor (anti-TNF) have significantly improved clinical outcomes. Partial, non- and transient responses remain common comprising significant unmet clinical need. New therapies with novel modes of action are urgently required. OBJECTIVES: The interleukin (IL)-17 pathway has recently been attributed a critical role in the pathogenesis of spondyloarthritides...
June 2016: Rheumatology and Therapy
https://www.readbyqxmd.com/read/27741340/secukinumab-self-administration-by-prefilled-syringe-maintains-reduction-of-plaque-psoriasis-severity-over-52-weeks-results-of-the-feature-trial
#17
Alice B Gottlieb, Andrew Blauvelt, Jörg C Prinz, Philemon Papanastasiou, Rashidkhan Pathan, Judit Nyirady, Todd Fox, Charis Papavassilis
BACKGROUND: Secukinumab, a human monoclonal antibody that selectively targets interleukin-17A, is highly efficacious in the treatment of moderate-to-severe psoriasis, starting at early time points, with a sustained effect and a favorable safety profile. METHODS: Patients with moderate-to-severe plaque psoriasis were randomized to secukinumab 300 mg, secukinumab 150 mg, or placebo self-administered by prefilled syringe at baseline, weeks 1, 2, and 3, and then every four weeks from week 4 to 48...
October 1, 2016: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/27718760/brodalumab-for-the-treatment-of-psoriasis
#18
M Galluzzo, S D'Adamio, L Bianchi, M Talamonti
Psoriasis is a complex disease in which the alteration of the IL-23/Th17 axis appears to be crucial for its pathogenic mechanisms, and anti-IL17 agents are rapidly becoming important therapeutic tools. Brodalumab, a fully human Chinese hamster ovary cell-derived immunoglobulin G2 (IgG2) anti-IL-17RA monoclonal antibody, is currently the most-developed treatment that binds to the IL-17RA. The authors review and provide updates of efficacy and safety by several studies on brodalumab. Areas covered: A PubMed search was performed for relevant literature...
October 10, 2016: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/27707593/secukinumab-shows-significant-efficacy-in-palmoplantar-psoriasis-results-from-gesture-a-randomized-controlled-trial
#19
Alice Gottlieb, John Sullivan, Martijn van Doorn, Alexey Kubanov, Ruquan You, Anne Parneix, Sophie Hugot, Marina Milutinovic
BACKGROUND: Plaque psoriasis affecting palms and soles is disabling and often resistant to treatment. OBJECTIVE: Evaluate the efficacy and safety of secukinumab, an anti-interleukin 17A antibody, in subjects with palmoplantar psoriasis. METHODS: In this double-blinded, randomized controlled trial, 205 subjects were randomized 1:1:1 to secukinumab 300 mg, 150 mg, or placebo. The primary endpoint was Palmoplantar Investigator's Global Assessment (ppIGA) 0 (clear) or 1 (almost clear/minimal) response at week 16...
October 1, 2016: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/27706476/successful-treatment-of-refractory-pityriasis-rubra-pilaris-with-secukinumab
#20
Daniel Schuster, Andrea Pfister-Wartha, Leena Bruckner-Tuderman, Christoph M Schempp
No abstract text is available yet for this article.
November 1, 2016: JAMA Dermatology
keyword
keyword
30575
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"